RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 190,000 shares, an increase of 29.2% from the December 31st total of 147,028 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
RemeGen Price Performance
Shares of REGMF stock opened at $10.45 on Tuesday. The firm has a 50-day moving average price of $10.11 and a 200 day moving average price of $8.66. RemeGen has a twelve month low of $9.81 and a twelve month high of $15.91.
About RemeGen
RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.
RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.
Read More
- Five stocks we like better than RemeGen
- The day the gold market broke
- Forget AI, This Will Be the Next Big Tech Breakthrough
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Gold’s getting scarce.
- ALERT: Drop these 5 stocks before the market opens tomorrow!
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
